| Popis: |
Purpose: The overriding goal of this study was to evaluate the safety of initiating and maintaining propranolol for problematic infantile hemangioma (IH) in neonates. Methods: Clinical data of 112 infants with IH admitted from January 2016 to December 2020 Department of Plastic Surgery, Jiangxi Provincial Children's Hospital were analyzed retrospectively. All of patients were evaluated during the hospital at the beginning of the treatment and later in outpatient settings during the treatment. Each time, the following monitoring methods were applied: physical examination, ultrasound echocardiography (UCG), electrocardiography (ECG), blood pressure (BP), heart rate (HR), and basic laboratory tests included blood glucose (BG), liver function, blood potassium, thyroid function. Results: There was a significant reduction in the BP and HR at the initiation of treatment. The incidences of bradycardia and hypoglycemia were observed to be increased with the prolong duration of treatment, but not prolonged PR interval. During the course of the therapy, the risk of hyperkalemia and hypothyroidism was reached maximum at the 2 months and 3 months, respectively. Physical growth index including average height, weight and head circumference was not influenced by the treatment. The observed adverse effects were majority mild and only 3 patients needed to rest for 7 days due to severe diarrhea before restarting treatment. Conclusions: Propranolol is safe and well-tolerated by properly selected young infants with IH. No serious adverse events were observed. Larger, prospective studies are indicated to investigate propranolol in young infants. |
